Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer

Launched by XUESONG LI · Nov 2, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with locally advanced ureteral cancer, a type of cancer affecting the tubes that carry urine from the kidneys to the bladder. The goal is to see if combining surgery that preserves kidney function with follow-up radiation therapy is safe and effective. This method aims to maintain kidney health while still effectively treating the cancer, which could help patients tolerate future treatments better compared to traditional surgery that removes the entire kidney.

To be eligible for this trial, participants need to be at least 18 years old and diagnosed with high-risk ureteral cancer. This includes patients with certain cancer characteristics, like aggressive tumor types or those with multiple cancer sites. Those interested in joining the trial will undergo some tests to ensure the cancer hasn't spread elsewhere in the body. Participants can expect to receive careful monitoring and follow-up throughout the study to assess the treatment's safety and effectiveness. It's important to note that individuals with certain medical histories or conditions may not qualify for the study, so discussing any concerns with a healthcare provider is crucial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - 1) Ureteral cancer patients with high-risk factors (high-risk factors define multifocal; G3; T2-4); surgery may be performed with patients undergoing partial terminal ureteral resection or radical nephroureterectomy 2)Age ≥18 years; 3)Completion of abdominopelvic CT 4 weeks before enrollment to exclude distant metastasis and regional lymph node metastasis.
• • 4) Patients did not have other malignant neoplastic diseases in the last 5 years except for non-melanoma of the skin and ductal carcinoma in situ of the breast; Willing to participate in perfecting the necessary examinations and follow-up for the sake of the study, and willing to provide written informed consent.
• Exclusion Criteria:
• • 1) Distant metastasis or retroperitoneal lymph node metastasis (N+) had been detected at the time of surgery; R2 resection patients; history of bladder cancer; 2) History of pelvic and abdominal radiotherapy; history of inflammatory bowel disease; history of systemic chemotherapy; 3) Pregnant women or breastfeeding women; or women of childbearing potential who are not practicing reliable contraception; (4) The presence of active infections in those with pre-existing or coexisting bleeding disorders 5) clinically significant cardiac disease (e.g., hypertension controlled with medications, unstable angina, New York Heart Association (NYHA) class ≥II congestive heart failure, unstable symptomatic arrhythmias, or class ≥II peripheral vascular disease); 6) Psychological, family, and social factors leading to lack of informed consent.